# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001493152-22-024147
Filing Date
2022-08-26
Accepted
2022-08-26 14:50:34
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | formdefa14a.htm | DEFA14A | 25309
2 |  | notice_01.jpg | GRAPHIC | 492579
3 |  | notice_02.jpg | GRAPHIC | 371591
| Complete submission text file | 0001493152-22-024147.txt |  | 1216338

Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39717 | Film No.: 221204457
SIC: 2834 Pharmaceutical Preparations